Singh Priya, Mishra Nidhi, Singh Neelu, Nisha Raquibun, Pal Ravi Raj, Singh Samipta, Maurya Priyanka, Saraf Shubhini A
Department of Pharmaceutical Sciences, SB&PS, Babasaheb Bhimrao Ambedkar University, Vidhyavihar, Raebareily Road, Lucknow, Uttar Pradesh India.
Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University, Vidya Vihar, Raebareli Road, Lucknow, U.P. 226025 India.
SN Compr Clin Med. 2020;2(11):2067-2076. doi: 10.1007/s42399-020-00526-3. Epub 2020 Sep 25.
The pandemic of coronavirus infection 2019 (COVID-19) due to the serious respiratory condition created by the coronavirus 2 (SARS-CoV-2) presents a challenge to recognize effective strategies for management and treatment. In general, COVID-19 is an acute disease that can also be fatal, with an ongoing 10.2% case morbidity rate. Extreme illness may bring about death because of enormous alveolar damage and hemorrhage along with progressive respiratory failure. The rapidly expanding information with respect to SARS-CoV-2 research suggests a substantial number of potential drug targets. The most encouraging treatment to date is suggested to be with the help of remdesivir, hydroxychloroquine, and many such repurposed drugs. Remdesivir has a strong in vitro activity for SARS-CoV-2, yet it is not the drug of choice as affirmed by the US Food and Drug Administration and presently is being tried in progressing randomized preliminaries. The COVID-19 pandemic has been the worst worldwide general health emergency of this age and, possibly, since the pandemic influenza outbreak of 1918. The speed and volume of clinical preliminaries propelled to examine potential treatments for COVID-19 feature both the need and capacity to create abundant evidence even in the center of a pandemic. No treatments have been demonstrated as accurate and dependable to date. This review presents a concise precise of the targets and broad treatment strategies for the benefit of researchers.
2019年冠状病毒感染（COVID-19）大流行，因严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引发的严重呼吸道疾病，给识别有效的管理和治疗策略带来了挑战。总体而言，COVID-19是一种急性疾病，也可能致命，目前病例发病率为10.2%。极端病症可能因巨大的肺泡损伤、出血以及进行性呼吸衰竭而导致死亡。关于SARS-CoV-2研究的信息迅速增加，提示了大量潜在的药物靶点。迄今为止，最令人鼓舞的治疗方法是使用瑞德西韦、羟氯喹以及许多其他重新利用的药物。瑞德西韦对SARS-CoV-2具有很强的体外活性，但美国食品药品监督管理局并未确认其为首选药物，目前正在进行的随机试验中对其进行检验。COVID-19大流行是这个时代乃至可能是自1918年大流行性流感爆发以来最严重的全球公共卫生紧急事件。为研究COVID-19潜在治疗方法而开展的临床试验的速度和规模，既体现了即便在大流行期间也迫切需要并能够产生大量证据。迄今为止，尚无治疗方法被证明准确可靠。本综述为研究人员简要概述了靶点和广泛的治疗策略。
